Page 5 - Targeted Augmentation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

BEDFORD, Mass., October 17, 2023--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that, effective on October 16th, 2023, the company granted a stock option to purchase an aggregate of 32,800 shares of common stock to 1 new employee, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Stoke Therapeutics, Inc. , a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that,...

– Mr. Smith brings significant experience in the successful development and commercialization of medicines for rare genetic diseases –BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating prote...

Stoke Therapeutics, Inc. , a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that...

– Mr. Smith brings significant experience in the successful development and commercialization of medicines for rare genetic diseases – ...